Related Experiment Video
Updated: Sep 27, 2025
Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
Published on: May 4, 2018
Update on the Neisseria Macrophage Infectivity Potentiator-Like PPIase Protein
1Neisseria Research Group, Molecular Microbiology, Academic School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton, United Kingdom.
Abstract:
Neisseria pathogens express a Macrophage Infectivity Potentiator Protein (MIP), which belongs to the FK506 binding protein (FKBP) family of proteins that exhibit peptidyl-prolyl cis/trans isomerase (PPIase) activity. Neisseria MIP proteins are potential candidates for inclusion into vaccines for gonorrhoea caused by N. gonorrhoeae infection, and meningitis/sepsis caused by M. meningitidis infection. Neisseria MIP proteins are also potential targets for directed drug treatments, although this remains relatively unexplored. In this mini-review, we provide an update into the vaccine potential of Neisseria MIP and the few published drug targeting studies, and explore further the diversity of this protein amongst both pathogenic and commensal Neisseria spp.
Insights
Neisseria Macrophage Infectivity Potentiator Proteins (MIP) show promise for vaccines against gonorrhea and meningitis. These FKBP proteins are also potential drug targets, with ongoing research exploring their diversity in Neisseria species.
Area of Science:
- Microbiology
- Immunology
- Drug Discovery
Background:
- Neisseria pathogens utilize a Macrophage Infectivity Potentiator Protein (MIP).
- MIP proteins belong to the FK506 binding protein (FKBP) family and possess peptidyl-prolyl cis/trans isomerase (PPIase) activity.
Purpose of the Study:
- To review the vaccine potential of Neisseria MIP proteins.
- To update on drug targeting studies for Neisseria MIP.
- To explore the diversity of MIP proteins across Neisseria species.
Main Methods:
- Literature review of Neisseria MIP vaccine candidates.
- Analysis of published drug targeting studies.
- Comparative analysis of MIP protein diversity.
Main Results:
- Neisseria MIP proteins are viable candidates for vaccines against N. gonorrhoeae and M. meningitidis.
- Limited drug targeting studies exist, indicating an underexplored area.
- Significant diversity of MIP proteins is observed among pathogenic and commensal Neisseria species.
Conclusions:
- Neisseria MIP proteins hold significant potential for both vaccine development and therapeutic strategies.
- Further research into drug targeting and MIP diversity is warranted.
- Understanding MIP diversity can inform the development of broad-spectrum Neisseria treatments.
